Tag: TACE

This advertorial is sponsored by Sirtex.  Interventional radiologists Thomas Albrecht (Vivantes Clinic Neukölln, Berlin, Germany) and Roberto Iezzi (Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy)...

Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...

Setting the audiences sights on the horizon at the 2023 Global Embolization Oncology Symposium (GEST, 18­–21 May, New York City, USA) yesterday, Daniel Sze...

A phase II clinical study on a trimodality therapy (START-FIT), conducted by the Departments of Surgery and Clinical Oncology, School of Clinical Medicine, University...

Interventional News 87 Highlights: Ten-year data on PAE for benign prostatic hyperplasia The success of interventional radiology outpatient clinics IR awareness: an initiative run...

NOTE: This video is ONLY available to watch in selected countries and geographies The “ideal patient” for a balloon-occluded transcatheter arterial chemoembolization (B-TACE) procedure...

NOTE: This video is ONLY available to watch in selected countries and geographies  Thierry De Baere (Villejuif, France) talks to Interventional News about the...

The sustained release of anthracyclines and durable embolization from LifePearl microspheres (Terumo Europe) makes transarterial chemoembolization (TACE) with these embolic agents a safe and...

Compared with doxorubicin-loaded drug-eluting embolic transarterial chemoembolization (DEE-TACE), conventional transarterial chemoembolization (cTACE) yielded a higher number of quality-adjusted life years (QALY) at a lower...

TriSalus Life Sciences (formerly Surefire Medical) has announced that the Centers for Medicare and Medicaid Services (CMS) granted approval for transitional pass-through (TPT) payment...

Ablation costs are significantly less than those of transarterial chemoembolization (TACE) and Yttrium-90 (Y-90), according to a comparative cost analysis of the three...

Transarterial chemoembolization using microspheres appears to show “much better outcomes” than those seen with conventional TACE, both in the setting of hepatocellular carcinoma (HCC)...

Aaron Abajian and Julius Chapiro, New Haven, USA, write about results from an early experiment in applying artificial intelligence (AI) and machine learning as a...

Transarterial chemoembolization (TACE) using LifePearl (Terumo) drug-eluting embolic agents in the treatment of hepatocellular carcinoma has just been published.

Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) announced that the first patient has been enrolled in CIREL (CIRSE registry for LifePearl microspheres),...

This approval also expands the number of chemotherapeutic drugs that can be loaded onto LifePearl to include idarubicin and epirubicin, a press release from...

“While both radial and femoral accesses are safe and effective for transarterial liver embolization, it is clear that the patients prefer radial access,” said Marcelo Guimaraes, Charleston, USA, who was presenting on the...

Mentice has announced the release of a new simulation training software for transarterial chemoembolization (TACE). The new software was showcased at the 2017 CIRSE...

A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in...

  The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for LifePearl Microspheres (CIREL), a new European-wide observational study that...

Guerbet has announced that the Thailand FDA has given approval of a new indication for Lipiodol Ultra-Fluide for selective hepatic intra-arterial injection for visualisation,...

Surefire, the developer of site-specific delivery devices for the interventional oncology market, has announced the first closing of a US$12.8 M Series D financing...

BTG International Canada has announced the commercial launch of DC Bead Lumi in Canada. The launch represents the first market commercialisation of DC Bead...